Background This study compared the treatment outcomes of patients with multidrug-resistant
tuberculosis (MDR-TB) before and after the implementation of public–private mix (PPM) …

SETTING: A referral centre in South Korea. OBJECTIVE: To investigate trends in drug
resistance, treatment modalities and outcomes, and adverse events of multidrug-resistant …

SETTING: After several changes in treatment modalities, it is time to re-evaluate treatment
outcomes of multidrug-resistant tuberculosis (MDR-TB). OBJECTIVE: To evaluate treatment …

BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) poses a threat to public health
as a result of high treatment costs and unsatisfactory outcomes. OBJECTIVE: To elucidate …

Background The treatment outcomes of patients with multidrug/rifampin-resistant (MDR/RR)
tuberculosis (TB) are important indicators that reflect the current status of TB management …

Background The increasing rate of drug-resistant tuberculosis (TB) is a threat to the public
health and TB control. In Korea, about 75~ 80% of TB patients are treated in private …

After decades of relatively little attention, the field of tuberculosis (TB) research has drawn
much attention in recent years. New anti-TB drugs, those already commercially available …

BACKGROUND: Treating multidrug-resistant TB (MDR-TB) remains challenging. However,
the determinants and timing of poor outcomes during MDR-TB treatment are still poorly …

SETTING: Resistance to the two key anti-tuberculosis drugs isoniazid and rifampicin is a
characteristic of multidrug-resistant tuberculosis (MDR-TB). MDR-TB is a scourge requiring …

Objectives The aim of this study was to retrospectively analyze the clinical outcome and the
risk factors associated with poor outcome of MDR-TB patients receiving standardized …